Jane Henderson, Chief Financial Officer at Apogee Therapeutics, Inc. (APGE), sold 8,000 shares at $80.00 ($609K) on 2026-01-06, disclosed to the SEC on 2026-01-06.
Scheduled sale ($609k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.13 | 1,920 | $142K | 23.4% |
| 2 | $75.20 | 4,080 | $307K | 50.4% |
| 3 | $80.00 | 2,000 | $160K | 26.3% |
| Total | $76.14 avg | 8,000 | $609K | 100% |
| Filing → |
| APGE | SELL | 2026-04-03 | $170K | — | Filing → |
| APGE | SELL | 2026-03-27 | $170K | — | Filing → |
| APGE | SELL | 2026-03-04 | $140K | — | Filing → |